TGF-β1 alters esophageal epithelial barrier function by attenuation of claudin-7 in eosinophilic esophagitis by Nguyen, N. et al.
TGF-β1 Alters Esophageal Epithelial Barrier Function by 
Attenuation of Claudin-7 in Eosinophilic Esophagitis
Nathalie Nguyen1,2,3, Shahan D. Fernando1,2,3, Kathryn A. Biette2,3, Juliet A. Hammer2,3, 
Kelley E. Capocelli1,2,4, David A. Kitzenberg3,4, Louise E. Glover3,4, Sean P. Colgan3,4, 
Glenn T. Furuta1,2,3, and Joanne C. Masterson1,2,3,6
1Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, 
Children’s Hospital Colorado, Aurora, Colorado, USA 2Gastrointestinal Eosinophilic Diseases 
Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, 
USA 3Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, 
Colorado, USA 4Department of Pathology, Children’s Hospital Colorado, Aurora, Colorado, USA 
5Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA 
6Institute of Immunology, Department of Biology, Maynooth University, Maynooth, Co. Kildare, 
Ireland
Abstract
Barrier dysfunction has been implicated in the pathophysiology of eosinophilic esophagitis (EoE). 
TGF-β1, a potent pleiotropic molecule, is increased in EoE, however, no study has evaluated its 
influence on esophageal epithelial barrier. We hypothesized that TGF-β1 regulates barrier 
dysfunction in EoE. We aimed to determine the role of TGF-β1 in epithelial barrier in models of 
EoE. To examine the impact of TGF-β1 on esophageal barrier, immortalized human esophageal 
epithelial (EPC2-hTERT) cells were exposed to TGF-β1 during the 3-dimensional air liquid 
interface (3D-ALI) model in vitro. TGF-β1 exposure diminished EPC2-hTERT barrier function as 
measured by transepithelial electrical resistance (TEER) and 3kDa FITC dextran paracellular flux 
(FITC Flux) and H&E assessment revealed prominent cellular separation. In analysis of epithelial 
barrier molecules, TGF-β1 led to the specific reduction in expression of the tight-junction 
molecule, claudin-7 and this was prevented by TGF-β receptor I inhibitor. shRNA mediated 
claudin-7 knockdown diminished epithelial barrier function, while claudin-7 overexpression 
resulted in protection from TGF-β1-mediated barrier dysfunction. In analysis of pediatric EoE 
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biopsies claudin-7 expression was decreased, altered localization was observed by 
immunofluorescence analysis and the TGF-β1 downstream transcription factor phosphorylated 
SMAD2/3 (pSMAD2/3) was increased. Our data suggest that TGF-β1 participates in esophageal 
epithelial barrier dysfunction through claudin-7 dysregulation.
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INTRODUCTION
Eosinophilic Esophagitis (EoE) is a chronic, immune/antigen mediated, inflammatory 
disease characterized by esophageal dysfunction and dense esophageal eosinophilia1. The 
esophageal epithelial architecture of patients with EoE is disrupted, characterized by dilated 
intercellular spaces and prominent basal cell hyperplasia2. A growing body of evidence 
implicates altered esophageal epithelial barrier in the pathophysiology of EoE. For instance, 
studies have shown decreased cell adhesion molecules such as desmoglein and epithelial 
barrier molecules such as filaggrin in EoE3–5. In addition, others have demonstrated barrier 
dysfunction in EoE patients at the electrophysiological level, suggesting impaired 
esophageal mucosa integrity6. Our previous work also demonstrated altered ultrastructural 
features with decreased desmosomes in active EoE7. To date, molecular mechanisms 
focused on the impact of type-2 cytokines, particularly IL-13, on regulating molecules 
associated with esophageal epithelial barrier3,4.
An increasing body of evidence suggests that transforming growth factor-β1 (TGF-β1), a 
pleiotropic cytokine that plays a critical role in immunoregulation, fibrosis and remodeling, 
participates in the pathogenesis of EoE. TGF-β1 signaling is increased in subjects with EoE 
and TGF-β1 itself is produced by a number of different cells including eosinophils, 
epithelial cells, and mast cells8–11. Although TGF-β1 protein has been difficult to quantify 
in esophageal tissue affected by EoE, biopsy specimens from subjects with EoE have 
demonstrated increased TGF-β1 mRNA and phosphorylated SMAD2/3 (pSMAD2/3) 
transcription factor protein immunostaining, a downstream nuclear signaling molecule in the 
TGF-β1 signaling pathway8,12,13. Studies have also shown that TGF-β1 plays a critical role 
in esophageal remodeling, participates in esophageal smooth muscle contraction, stimulates 
fibroblast secretion of extracellular matrix, and contributes to esophageal epithelial to 
mesenchymal transitions (EMT) in vitro10,14–18 and in vivo8,19,20. In vitro models have 
shown that TGF-β1 alters epithelial barrier function in other epithelial cell types, including 
columnar epithelium of the lung and pseudostratified epithelium of the epididymis and vas 
defrens21–23, however, no study has evaluated the influence of TGF-β1 on stratified 
squamous epithelial barriers including the esophageal epithelium. Therefore, we sought to 
determine the role of TGF-β1 on epithelial barrier function in the pathogenesis of EoE. We 
hypothesized that TGF-β1 regulates epithelial barrier dysfunction in EoE.
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METHODS
Human Esophageal Epithelial Cell Line in Air Liquid Interface Culture System
Immortalized human esophageal epithelial (EPC2-hTERT)24 cells (kind gift from Drs. Anil 
Rustgi and Hiro Nakagawa, University of Pennsylvania), claudin-7 knockdown cells, or 
claudin-7 overexpressing cells were used for cell culture studies. To generate a human 
CLDN7 expression construct, full length claudin-7 open reading frame (ORF) 
(NM_001307) was amplified from plasmid mEmerald-claudin7-C-12 (Plasmid 54041; 
Addgene, Cambridge, MA) by polymerase chain reaction (PCR) using sense primer 5′-
AAAGCTAGCAATGGCCAATTCGGGCCTGCAGTT-3 (incorporating a Kozak translation 
initiation sequence and 5′ NheI restriction site) and antisense primer 5′-
TTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGG-3′. CLDN7 ORF was digested to 
generate NheI-CLDN7-XbaI for subcloning into lentiviral pLKO.1-puro plasmid with CMV 
promoter (Addgene, Cambridge, MA) linearized by NheI/XbaI restriction digest. Digested 
CLDN7 and linearized pLKO.1 vector were purified (WizardPrep Column, Promega, 
Madison, WI) for ligation using T4 DNA ligase (New England Biolabs, Ipswich, MA). 
Constructs were verified by sequencing (Molecular Biology Service Center, University 
Colorado) and packaged into lentiviral particles using 293TN cells (SBI, Palo Alto, CA) and 
MISSION Lentiviral Packaging mix as previously described (Sigma Aldrich, St. Louis, 
MO).
To develop claudin-7 knockdown cells, EPC2-hTERT cells were transduced with short 
hairpin ribonucleic acid (shRNA) lentiviral constructs targeting claudin-7 and a scrambled 
shRNA as a control (MISSION TRC, Functional Genomics Core, University of Colorado, 
Boulder) as previously described25. To develop claudin-7 overexpressing cells, EPC2-TERT 
cells were transduced with the above generated lentiviral construct containing pLKO-
claudin-7 overexpressing constructs (pLKO.1-Puro claudin-7 ORF) as previously 
described25. Forty eight hours after transduction, cells were selected for stable integration 
using puromycin (0.3μg/ml, Sigma Aldrich, St. Louis, MO).
The 3-dimensional air liquid interface (3D-ALI) culture system was used, as previously 
described4,26. In brief, EPC2-hTERT cells, claudin-7 knockdown cells, or claudin-7 
overexpressing cells were submerged in keratinocyte serum-free media (KSFM) (Thermo 
Fischer, Waltham, MA) and grown to confluence on 0.4 μm pore-size permeable transwells 
(Corning, Corning, NY). Once the cells reached confluence, on day 2, they were placed in 
high calcium KSFM ([Ca2+]=1.8 mM) for an additional 5 days to induce terminal 
differentiation. To induce stratification, media was removed from the upper chamber in order 
to expose the cells to air liquid interface for a 4 day period. Treatment with recombinant 
human TGF-β1 (R&D Systems, Minneapolis, MN, 10 ng/ml) in the basal chamber occurred 
at the start of 3D-ALI exposure and during the process of differentiation and stratification on 
days 7 and 9. Cells were collected for analysis of RNA or protein expression and for 
histologic analysis as previously described4.
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Esophageal Epithelial Barrier Measurements
Functional assays of barrier were performed on the 3D-ALI culture system using 
transepithelial electrical resistance (TEER) with a commercial Ohmmeter (WPI, Sarasota, 
FL) as previously described25. In vitro measurements for TEER were assessed on day 11 of 
cells grown at 3D-ALI in TGF-β1 treated cells or on claudin-7 knock down cells.
Paracellular 3kDa FITC Dextran flux assays were also completed on TGF-β1 treated EPC2-
hTERT and claudin-7 knock down cells that were grown at 3D-ALI on 0.4 μm permeable 
polyester membrane inserts on day 11 of culture. Following washing, FITC-Dextran (62.5 
μg/ml, 3kDa, Molecular Probes) was placed into the apical chamber. Samples were 
harvested from the basal chamber every 30 minutes for 90 minutes after to determine rate of 
flux. Fluorescent spectrophotometry was performed to analyze samples.
TGF-β1 Inhibition
EPC2-hTERT cells were cultured as previously described24. EPC2-hTERT cells were seeded 
at 125,000 cells per well of a 24-well plate. Twenty-four hours after the cells were plated, 
they were washed and treated with SB431542, a selective inhibitor of TGF-β type 1 receptor 
(S4317, Sigma Aldrich, St. Louis, MO, 5μm) for 4 hours. After 4 hours, the cells were 
treated with recombinant human TGF-β1 (R&D Systems, Minneapolis, MN, 10 ng/ml) in 
combination with the selective TGF-β type 1 receptor inhibitor (S4317, Sigma Aldrich, St. 
Louis, MO, 5μm) for 48 hours. Cells were harvested for mRNA analysis using RLT buffer 
from Qiagen RNeasy kits (Qiagen, Valencia, CA).
RNA Isolation and quantitative RT-PCR
RNA from cells in 3D-ALI and human esophageal biopsies were isolated using RNeasy kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions and cDNA made using 
a high-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). 
Junctional molecule expression was measured by Real-time Reverse Transcription 
Polymerase Chain Reaction (RT-PCR) using TaqMan gene expression assays with TaqMan 
probes (Applied Biosystems, Foster City, CA) targeting E-Cadherin, desmoglein-1, 
desmoglein-2, desmoglein-3, claudin-1, claudin-4, claudin-7, occludin, zonula occluden-1, 
connective tissue growth factor, smooth muscle α actin, and N Cadherin. Data were 
normalized to the house keeping gene, 18S, and were calculated for each sample as relative 
quantity RQ = 2−ΔΔCt, where Ct is the cycle threshold.
Western Blot Analysis
Protein lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer (Sigma 
Aldrich, St. Louis, MO) and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, 
IN). Protein electrophoresis was performed using 12% polyacrylamide gels. Blots were 
probed with the primary antibody overnight and incubated with appropriate HRP labeled 
secondary antibodies for 1 hour at room temperature. Visualization was performed using a 
chemiluminescent detection system (SuperSignal West PICO, Thermo Fischer, Waltham, 
MA). Primary antibodies used include claudin-7 polyclonal rabbit antibody (#34-9100, 
Invitrogen, Carlsbad, CA), pSMAD2/3 polyclonal rabbit antibody (#8828, Cell Signaling 
Technology, Danvers, MA), SMAD2/3 monoclonal mouse antibody (#610843, BD 
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Biosciences, San Jose, CA) and β-Actin (#8227, Abcam, Cambridge, MA). Quantification 
was assessed using comparative densitometry with β-actin as a loading control.
Immunohistochemical & Immunofluorescent Staining
Cells grown at 3D-ALI were fixed with 10% neutral-buffered formalin, processed, and 
paraffin embedded. Sections were cut into 5 μM sections and stained with hematoxylin and 
eosin (H&E) (Sigma Aldrich, St. Louis, MO). Immunofluorescent staining was performed 
on formalin fixed, paraffin-embedded esophageal biopsy samples that were cut into 5 μM 
sections. Samples were deparaffinized via sequential immersion with xylene followed by 
graded ethanol immersion and rehydration. Heat induced antigen retrieval in sodium citrate 
buffer (Vector Laboratories, Burlingame, CA) was used. Sections were blocked in 5% 
bovine serum albumin in tris-buffered saline for 30 minutes. Primary antibodies claudin-7 
(1:100, #51-900, Invitrogen, Carlsbad, CA) or pSMAD2 (1:2000, #3101, Cell Signaling 
Technology, Danvers, MA) were used and slides were incubated at 4 degrees overnight. 
Slides were washed and incubated for 30 minutes at room temperature in secondary 
antibody of Alex Fluor 488 Goat anti-rabbit IgG or Alexa Fluor 555 Goat anti rabbit IgG 
(Invitrogen, Carlsbad, CA). Slides were washed followed by counterstaining with DAPI and 
mounted for visualization. Images were acquired using an Olympus IX83 microscope and 
cellSens v1.14 software.
Characterization of human subject samples
Healthy control subjects underwent upper intestinal endoscopy for indications including 
abdominal pain, feeding difficulty, poor weight gain, and diarrhea and had normal 
esophageal histology with a mean eosinophil count of 0 eosinophils per high power field 
(eos/HPF). The mean age was 8.2±4.1 years in these subjects. Active EoE subjects had 
symptoms of esophageal dysfunction and ≥15 eos/HPF in whom other causes for 
eosinophilia had been ruled out according to consensus recommendations1. Symptoms 
included abdominal pain, dysphagia, feeding difficulty, poor weight gain, and vomiting. 
Active EoE subjects had a mean eosinophil count of 46.5±34.9 eos/HPF and the mean age 
was 8.7±5.1 years. Inactive EoE subjects had an established diagnosis of EoE who 
underwent treatment with topical corticosteroids or dietary elimination with resolution of 
symptoms and <15 eos/HPF. These subjects had a mean eosinophil count of 1.8±2.9 
eos/HPF and the mean age was 7.2±4.0 years. Written informed consent was obtained and 
all human studies were approved by the Colorado Multi-Institutional Review Board.
Statistical Analysis
Statistical analysis of data was performed by students’ t-test and one-way analysis of 
variance (ANOVA) where appropriate. A p-value of ≤ 0.05 was considered statistically 
significant, although in some cases higher levels of significance are noted when applicable 
(*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤ 0.0001). GraphPad Prism 7 (GraphPad Software, 
LaJolla, CA) was used to perform statistical analysis and generate figures.
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RESULTS
TGF-β1 alters esophageal epithelial barrier
To investigate the functional consequences of transforming growth factor-β1 (TGF-β1) on 
esophageal epithelia, we measured barrier by transepithelial electrical resistance (TEER) and 
paracellular permeability by 3kDa FITC Dextran Flux (FITC Flux) in immortalized human 
esophageal epithelial (EPC2-hTERT) cells grown in a physiologically relevant 3-
dimensional air liquid interface (3D-ALI) model in vitro where cells undergo stratification 
and squamation. We found that TGF-β1 (10 ng/ml) exposure resulted in a significant 
attenuation of barrier, as measured by TEER, compared to unstimulated control cells 
(446.6±29.7 vs 323.1±15.6. ohms.cm2, Control vs TGF-β1 10 ng/ml, N=8, p≤0.01) (Figure 
1A). We evaluated the epithelial paracellular permeability using 3kDa FITC Flux and found 
a significant increase in paracellular flux in the epithelium exposed to TGF-β1 (10 ng/ml) 
when compared to unstimulated cells (1.00±0 vs 1.47±0.15 fold, Control vs TGF-β1 10 
ng/ml, N=4, p≤0.05) (Figure 1B). We performed a histological analysis of EPC2-hTERT 
cells grown in a physiologically relevant 3D-ALI model. H&E stained sections of EPC2-
hTERT cells grown in 3D-ALI had normal stratification and differentiation (Figure 1C, top 
panel). However, TGF-β1 (10 ng/ml) treated cells grown in 3D-ALI had prominent cell 
separation, particularly in the basal and suprabasal layers (Figure 1C, bottom panel).
Because activation of the canonical TGF-β1 pathway leads to phosphorylation of SMAD2/3, 
we performed western blot of phosphorylated SMAD2/3 (pSMAD2/3) to confirm the effect 
of TGF-β1 at the signaling level in the 3-D ALI model. We found that TGF-β1 (10 ng/ml) 
exposure resulted in an increase in pSMAD2/3 protein expression (1.00±0.34 vs 2.16±0.46, 
Control vs TGF-β1 10 ng/ml, N=4, p≤0.05) and decrease in total SMAD 2/3 protein 
expression (1.00±0.08 vs 0.55±0.03, Control vs TGF-β1 10 ng/ml, N=4, p≤0.01) compared 
to unstimulated control cells, as measured by densitometry indicating that TGF-β1 activates 
SMAD2/3 via phosphorylation in the in vitro 3-D ALI model (Figure 1D–F).
TGF-β1 attenuates expression of tight junction claudin-7 in vitro
In light of the functional barrier changes observed after exposure to TGF-β1, we sought to 
understand the expression patterns of various epithelial cell-cell junction barrier molecules 
in 3D-ALI cells following TGF-β1 exposure. We analyzed transmembrane epithelial barrier 
molecule expression of the epithelial cell-cell junctions including tight junctions, adherens 
junctions and desmosomes using real time reverse transcription polymerase chain reaction 
(RT-PCR). These molecules were targeted because they are the transmembrane proteins 
involved in cell-cell junctions important in epithelial barrier function. In particular, we 
performed an array analysis using real time RT-PCR to determine which claudins were 
present in the esophageal epithelium using EPC2-hTERT cells. Consistent with previous 
literature in the field27–29 we found that claudin 1, 4 and 7 were the predominantly 
expressed claudins in the esophageal epithelium differentiated at 3D-ALI (Figure 2A). We 
subsequently found the specific and significantly attenuated expression of claudin-7 
(CLDN7) mRNA in 3D-ALI cells exposed to TGF-β1 (10 ng/mL) when compared with 
unstimulated cells (0.93±0.10 vs 0.42±0.02, Control vs TGF-β1 10 ng/ml, N=3, p≤0.01) 
(Figure 2B). However, no significant differences were observed in other epithelial barrier 
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molecules including adherens junction components (E-Cadherin), desmosomes 
(desmoglein-1, desmoglein-2, and desmoglein-3), or tight junction components (claudin-1, 
claudin-4, occludin, and zonula occluden-1) (Table 1). Additionally, there were no 
significant differences in mesenchymal genes including connective tissue growth factor or 
alpha smooth muscle actin. There was however a significant increase in N-Cadherin. With 
no concomitant decrease in E-Cadherin in our cells following 5 days of culture at 3D-ALI in 
the presence of TGF-β1, this does not meet the definition of epithelial mesenchymal 
transition (EMT)30 (Table 1). Western blot analysis of cell lysates showed consistent 
findings, with a significant decrease in protein expression of claudin-7 relative to 
unstimulated cells as measured by densitometry (1.00±0.17 vs 0.28±0.12, Control vs TGF-
β1 10 ng/ml, N=3, p≤0.05,) (Figure 2C & 2D). To determine if inhibition of the TGF-β1 
SMAD pathway would protect against the TGF-β1 mediated attenuation in claudin-7, we 
exposed esophageal epithelial cells to SB431542, a selective inhibitor of TGF-β type 1 
receptor, prior to TGF-β1. We found that when cells were exposed to TGF-β1, there was an 
expected attenuation in claudin-7, however when cells were exposed to TGF-β type 1 
receptor inhibitor (TGF-β RI) prior to TGF-β1, cells were protected from the TGF-β1 
mediated claudin-7 attenuation, indicating that the TGF-β1 pathway directly influences the 
attenuation of claudin-7 (1.00±0 vs 0.08±0.02 vs 1.38±0.17, Control vs TGF-β1 10 ng/ml vs 
TGF-β type 1 receptor inhibitor 5μm, N=4, p≤0.01) (Figure 2E).
Claudin-7 knockdown results in esophageal epithelial barrier dysfunction in vitro
In order to assess whether TGF-β1’s role was mediated, at least in part, through the 
suppression of CLDN7 expression, we generated CLDN7 knockdown cells using shRNA 
mediated approach and examined barrier function in these esophageal cells. To first validate 
the level of CLDN7 suppression in our cells, we examined CLDN7 mRNA and claudin-7 
protein expression levels. We found our cells to have 97% reduction in CLDN7 mRNA 
expression (1.00±0 vs 0.03±0.004, shRNA control vs shRNA CLDN7 KD, N=3, p≤0.0001) 
as compared to control cells (Figure 3D). This resulted in a 90% reduction in claudin-7 
expression at the protein level (1.00±0 vs 0.098±0.091, shRNA control vs shRNA CLDN7 
KD, N=3, p≤0.01) as compared to control cells (Figure 3A–C). Specificity for CLDN7 was 
confirmed by assessing the expression of other related esophageal claudins at the protein 
level by western blot, including claudin-1 (1.00±0 vs 1.16±0.28, shRNA control vs shRNA 
CLDN7 KD, N=2, n.s.) and claudin-4 (1.00±0 vs 0.61±0.1, shRNA control vs shRNA 
CLDN7 KD, N=2, n.s.). No significant effects on these associated molecules were observed 
(Figure 3A & 3B).
Functional barrier assessments of CLDN7 knockdown cells in the 3D-ALI model were 
performed to evaluate the importance of this specific molecule on esophageal epithelial 
barrier. We found a significant decrease in TEER (437.4± 19.5 vs 336.0±23.5 ohms.cm2, 
shRNA control vs shRNA CLDN7 KD, N=12, p≤0.01) and a parallel increase in paracellular 
flux (1.00±0 vs 1.54±0.31, shRNA control vs shRNA CLDN7 KD, N=11, p≤0.05) when 
compared to control cells (Figure 4A & 4B). We performed a histological analysis of these 
cells in the 3D-ALI model. H&E stained sections of CLDN7 knockdown cells grown in 3D-
ALI exhibit prominent cell separation, particularly in the basal and suprabasal layers (Figure 
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4C, bottom panel) when compared to control cells, which displayed normal epithelial 
stratification (Figure 4C, top panel).
Additionally, we generated CLDN7 overexpressing cells (pLKO.1-Puro claudin-7 ORF) and 
compared functional assessments in these esophageal cells in the presence and absence of 
TGF-β1 () in the 3-D ALI model. Claudin-7 overexpressing cells, pLKO.1-Puro claudin-7 
ORF, were validated and had 4.9 fold increase in mRNA expression and 2.5 fold increase in 
protein expression by western blot compared to control cells, pLKO.1-Puro EV. When 
pLKO.1-Puro claudin-7 ORF cells were grown in the presence and absence of TGF-β1, 
there was no significant decrease in TEER (376.2± 46.8 vs 341.0±53.1 ohms.cm2, pLKO.1-
Puro claudin-7 ORF without TGF-β1 versus pLKO.1-Puro claudin-7 ORF with TGF-β1 10 
ng/ml, N=5, n.s.) or increase in paracellular flux (1.00±0 vs 1.40±0.30, pLKO.1-Puro 
claudin-7 ORF without TGF-β1 versus pLKO.1-Puro claudin-7 ORF with TGF-β1 10 
ng/ml, N=4, n.s.) compared to control cells following TGF-β1 exposure (Figure 4D & 4E). 
We performed a histological analysis of CLDN7 overexpressing cells in the 3D ALI model. 
H&E stained sections of these cells grown in 3D-ALI had normal stratification and 
differentiation (Figure 4F, top panel). CLDN7 overexpressing cells exposed to TGF-β1 (10 
ng/ml) in the 3D-ALI model did not exhibit the same degree of cell separation as either 
EPC-hTERT cells exposed to TGF-β1 or as CLDN7 KD cells (Figure 4F, bottom panel). 
These results show that overexpression of claudin-7 in the presence of TGF-β1, will 
partially but not completely, protect the epithelial barrier and indicates that TGF-β1 impairs 
the barrier in part through a claudin-7 dependent manner. Our findings suggest that in the 
setting of attenuated claudin-7, even in the absence of other potential effects of TGF-β1, 
epithelial barrier defects exist. This finding suggests that suppression of claudin-7 in 
response to TGF-β1 exposure plays an important role in esophageal epithelial barrier 
integrity in vitro.
Claudin-7 expression is attenuated in pediatric subjects with active EoE
We next sought to evaluate the clinical relevance of these in vitro findings. Pediatric subjects 
were characterized by disease activity based on clinical symptoms and histopathology. We 
evaluated esophageal biopsies from active eosinophilic esophagitis (EoE) subjects (N=7), 
inactive EoE subjects (N=6) and healthy controls (N=10).
Consistent with our in vitro findings, we found that CLDN7 mRNA expression was 
significantly decreased in subjects with active EoE compared to control subjects. In addition, 
following successful treatment of EoE, in inactive EoE subjects, CLDN7 mRNA expression 
was restored to similar levels as in our control subjects (1.00±0.10 vs 0.30±0.10 vs 
0.97±0.13, control subjects vs active EoE subjects vs inactive EoE, N=6–10 per group, 
p≤0.001) (Figure 5). We next performed immunofluorescent staining for claudin-7 protein in 
esophageal biopsies in order to characterize its expression pattern and localization. Control 
and inactive EoE subjects showed a crisp continuous linear pattern outlining the cell 
membrane in the suprabasal layer of the epithelium with a honeycomb appearance. 
However, claudin-7 immunofluorescence in active EoE subjects showed a diffuse granular 
perimembraneous pattern outlining the cell membrane in addition to increased staining 
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present within in the cytoplasm of the cells. This was particularly the case in cells of the 
suprabasal layers. (Figure 6 A–C).
TGF-β1 signaling increased in EoE
Because activation of the canonical TGF-β1 pathway leads to phosphorylation of SMAD2/3 
and nuclear translocation of SMAD complexes that affect gene transcription31, we evaluated 
phosphorylated SMAD2/3 (pSMAD2/3) in active EoE subjects compared to controls and 
inactive EoE subjects. pSMAD2 staining was present in both the lamina propria and the 
epithelium of subjects with active EoE, similar to previously published findings8. Future 
studies better powered to focus on the functional effects of lamina propria pSMAD2/3 
should be pursued. However, for our focus on TGF-β1’s effect on the epithelium, we found 
increased nuclear pSMAD2 staining in esophageal epithelial cells in active EoE subjects 
compared to control and inactive EoE (500±54 vs 695±61 vs 504±35 positively stained 
epithelial cells per high power field, N=3 × 3 fields of 40× view, p≤0.05) (Figure 7A–D) 
indicating increased TGF-β1 signaling in the epithelium of subjects with active EoE. In 
addition, semi-quantitative analysis of pSMAD2/3 protein expression by western blot was 
consistent with these findings, with increased expression in active EoE when compared to 
control and inactive EoE subjects as measured by densitometry (1.17±0.20 vs 3.17±0.64 vs 
1.88±0.47, control subjects vs active EoE subjects vs inactive EoE subjects, N=6 per group, 
p≤0.05) (Figure 7E–F). To determine whether the regulation of SMAD2/3 is at the activation 
or expression level, total SMAD2/3 was also assessed by western blot in a cohort of these 
samples. There was no significant difference in total SMAD2/3 protein expression observed 
between control, active and inactive EoE subjects (1.00±0.41 vs 2.06±0.70 vs 2.92±1.21, 
normal subjects vs active EoE subjects vs inactive EoE subjects, N=3–4 per group, n.s.), 
indicating that there is an increase in the activation of SMAD2/3 by phosphorylation in 
active EoE subjects (Figure 7G).
DISCUSSION
In this study, we demonstrate that transforming growth factor-β1 (TGF-β1) leads to 
functional esophageal epithelial barrier defects in vitro. We show that esophageal epithelial 
cells cultured in 3-dimensional air liquid interface (3D-ALI) stratified squamous cultures 
exposed to TGF-β1 led to a specific attenuation of claudin-7 expression and that shRNA-
mediated knockdown results in barrier defects, indicating a role for claudin-7 in maintaining 
epithelial barrier integrity. Notably, we demonstrate that claudin-7 expression is decreased 
and phosphorylated SMAD2/3 (pSMAD2/3) is increased in pediatric subjects with active 
EoE when compared to control and inactive EoE subjects. The results herein suggest that the 
down regulation of claudin-7 by TGF-β1 plays a role in epithelial barrier dysfunction in 
eosinophilic esophagitis (EoE).
Our data shows that in the presence of TGF-β1, transepithelial electrical resistance (TEER) 
decreases and 3 kDa FITC Dextran Flux (FITC flux) increases, suggesting that TGF-β1 
leads to an impaired epithelial barrier. Recent clinical studies implicate epithelial barrier 
dysfunction in the pathogenesis of EoE, including dilated intercellular spaces and decreased 
electrical impedance in subjects with active EoE5,32,33. Additionally, in translational studies, 
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decreased expression of junctional cell cell adhesion complex molecules, such as 
desmoglein and barrier forming filaggrin, further suggests an impaired epithelial barrier in 
EoE3,4,7,34. Some of these studies have focused on the impact of the type-2 cytokine IL-13 
as a mediator of the negative regulation of epithelial barrier molecules associated with 
esophageal epithelium3,4. Our study adds to the growing body of evidence that altered 
epithelial barrier plays a role in the pathogenesis of EoE and indeed is the first study to 
examine the importance of claudin-7 in esophageal epithelial barrier function. Other studies 
have shown important roles for this molecule in the simple columnar epithelium of the colon 
and the cuboidal epithelium of the salivary glands35,36. In vitro models examining the role of 
TGF-β1 and impaired epithelial barrier function has been evaluated in other epithelia types, 
including the columnar epithelia of the lung, pseudostratified epithelium of the epididymis 
and vas defrens, however this has not been previously examined the in stratified epithelium 
or indeed the esophagus21–23. Our study is the first to show the effect of TGF-β1 on altered 
epithelial barrier function and specifically the key role of claudin-7 in the esophagus. 
Previous EoE studies have shown that TGF-β1 plays a role in esophageal remodeling, 
participates in esophageal smooth muscle contraction, stimulates fibroblast secretion of 
extracellular matrix, and contributes to esophageal epithelial to mesenchymal transition 
(EMT)8,10,14–20. Our findings suggest that it is possible that chronic TGF-β1 mediated 
altered esophageal epithelial barrier or increased esophageal epithelial permeability may 
allow passage of allergens that enhances antigen presentation an immune activation and 
contributes in a previously unconsidered way to the chronicity of disease in EoE patients, 
though this would require further examination outside the remit of the current studies.
The findings in our study demonstrate that claudin-7 is down-regulated both at the 
transcriptional and translational/post-translational level in the presence of TGF-β1. The 
claudin family of proteins are transmembrane proteins found in tight junctions that fall into 2 
functional categories: barrier-forming claudins that serve to tighten the barrier or pore 
forming claudins that increase permeability37. Tight junctions serve as a barrier to 
paracellular permeability by forming a seal between epithelial cells and are important to the 
integrity of the epithelial barrier37. Claudin-7 is a barrier-forming claudin found in the 
epithelium of a variety of tissues37. Several previous studies have shown that claudin-1 and 
claudin-4, which are both barrier-forming claudins, are affected in in vitro models of 
gastroesophageal reflux disease (GERD) in conjunction with increased permeability and 
decreased transepithelial electrical resistance, indicating a disrupted epithelial barrier27,28. In 
addition, the esophageal epithelium in subjects with GERD has significantly decreased 
claudin-1 and claudin-4 expression29. After exposure to TGF-β1 in vitro, we did not see a 
significant decrease in claudin-1 or claudin-4, which was previously shown in subjects with 
GERD. Instead, we observed a significant and specific decrease in claudin-7, indicating that 
this is specific to TGF-β1 signaling. In addition, in pediatric subjects with active EoE, we 
found that claudin-7 expression was significantly decreased as compared to control subjects, 
suggesting that the attenuation in claudin-7 may be specific to TGF-β1 signaling in EoE and 
is important for esophageal barrier function.
In pediatric subjects with active EoE, we show that pSMAD2/3, is increased when compared 
to normal subjects and inactive EoE subjects, suggesting increased TGF-β1 signaling 
activity in the esophageal epithelium in active EoE. This is consistent with previous studies 
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that have shown increased TGF-β1 and pSMAD2/3 in active EoE with the cellular source of 
TGF-β1 being eosinophils, mast cells and epithelial cells8–11. In the canonical SMAD 
dependent TGF-β1 signaling pathway, binding of TGF-β1 to TGF-β receptors I and II 
allows TGF-β receptor II to trans phosphorylate TGF-β receptor I leading to the 
phosphorylation of SMAD 2 and 331. pSMAD2/3 complexes with the common SMAD4 and 
trans-locates into the nucleus31. SNAI1, a transcription repressor, in complex with SMAD in 
the canonical TGF-β1 signaling pathway, has been shown to target the gene promoter of 
several tight junction molecules, specifically claudin-3 and E-cadherin in breast epithelial 
cells38. In other systems, SNAI1 plays a role in transcriptional repression of claudin-739–41. 
Other regulators of claudin-7 include hepatocyte nuclear factor 4alpha 36. Therefore, a 
potential mechanism for the attenuation of claudin-7 is through the TGF-β1 signaling 
pathway with induction of the SMAD/SNAI1 transcriptional repressor complex leading to 
the transcriptional repression of claudin-7 with resulting epithelial barrier dysfunction. 
Specifically, in vitro lung injury models revealed that TGF-β1 reduced levels of claudin-521. 
In vitro models of the vas deferens, which is a columnar epithelium, have shown that TGF-
β1 disrupts epithelial barrier with attenuation in claudin-723. Our study shows a specific 
attenuation of claudin-7 and decreased barrier function in esophageal epithelial cells after 
exposure to TGF-β1. We show that in the esophagus, which is a stratified squamous 
epithelium, subjects with active EoE have a reduction in claudin-7 and alterations in the 
localization of claudin-7. We also demonstrate that knockdown of claudin-7 in esophageal 
epithelial cells resulted in a significant decrease in barrier function as measured by 
decreased TEER and increased paracellular permeability as measured by FITC flux 
implicating the importance of this molecule in esophageal epithelial barrier function, and the 
lack of redundancy with other claudin molecules expressed in the esophagus. Overall, our 
data suggests that claudin-7 plays a key role in maintaining the esophageal epithelial barrier 
function.
There are limitations to our study. First, our findings of esophageal epithelial barrier 
dysfunction are from in vitro studies and those with EoE patient biopsies. Future functional 
studies evaluating mucosal integrity by intraluminal impedance in conjunction with 
evaluating cell adhesion molecules, such as claudin-7, and activation of the TGF-β1 
signaling pathway are further needed. Second, earlier studies illustrated a role for TGF-β1 in 
EMT20. Unique to original studies on submerged cells the focus of this study was to 
determine the effects of TGF-β1 specifically on epithelial barrier in cells grown in an 
organotypic fashion. Although cells exposed to TGF-β1 in this 3D-ALI environment 
increased N-cadherin expression, it did not decrease E-cadherin expression. Loss of E-
cadherin is a key event in the EMT cascade. By definition, Kalluri and Weinberg classify 
EMT as a process in which an epithelial cell completely loses its polarized, barrier forming 
identity in turn for a mesenchymal state that functionally includes enhanced migration and 
invasiveness, increased apoptotic resistance, and the greatly increased production of extra-
cellular matrix components42. Our studies, found a specific and significant decrease in 
CLDN7, an increase in N-cadherin and no change in E-cadherin immediately in response to 
TGF-β1 exposure. In future studies, longer-term exposure to TGF-β1 at ALI culture may 
lead to a functional EMT-like process that will critically involve the loss of epithelial 
molecular and functional phenotypes. EMT plays an important role in wound healing 
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following inflammation and injury. Pathological fibrosis can arise from excessive wound 
healing, a process in which TGF-β1 has been shown to play a key role 31. In EoE, studies 
have shown that TGF-β1 plays a role in esophageal remodeling, esophageal smooth muscle 
contraction, EMT, and fibroblast secretion of extracellular matrix in vitro10,14–18 and in 
vivo8,19,20. Thus, TGF-β1 may not only play a role in EoE as it relates to EMT and fibrosis, 
but also in epithelial barrier dysfunction.
In summary, our findings indicate a pathogenic role for TGF-β1 in esophageal barrier 
dysfunction. TGF-β1, which is elevated in EoE, leads to alterations in epithelial barrier 
function, specifically through diminishing claudin-7 expression. With the growing body of 
clinical evidence suggesting a role of altered barrier in EoE specifically, and in atopic 
diseases in general, our findings support a potential role for TGF-β1 in this process. The 
advent of TGF-β1 inhibiting therapeutics presents an opportunity to consider this novel 
therapeutic approach that could alter both fibrotic as well as barrier alterations in EoE.
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pSMAD2/3 phosphorylated SMAD2/3
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RT-PCR Reverse Transcription Polymerase Chain Reaction
shRNA Short hairpin ribonucleic acid
TEER Transepithelial electrical resistance
TGF-β1 Transforming growth factor-β1
TGF-β RI TGF-β type 1 receptor inhibitor
References
1. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus 
recommendations for children and adults. J Allergy Clin Immunol. 2011; 128:3–20 e6. [PubMed: 
21477849] 
2. Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal 
diseases. Gastroenterol Clin North Am. 2014; 43:257–68. [PubMed: 24813514] 
3. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial 
differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010; 184:4033–41. [PubMed: 
20208004] 
4. Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and 
immune responses in eosinophilic esophagitis. Mucosal immunology. 2014; 7:718–29. [PubMed: 
24220297] 
5. Katzka DA, Tadi R, Smyrk TC, et al. Effects of topical steroids on tight junction proteins and 
spongiosis in esophageal epithelia of patients with eosinophilic esophagitis. Clin Gastroenterol 
Hepatol. 2014; 12:1824–9 e1. [PubMed: 24681080] 
6. van Rhijn BD, Kessing BF, Smout AJ, Bredenoord AJ. Oesophageal baseline impedance values are 
decreased in patients with eosinophilic oesophagitis. United European gastroenterology journal. 
2013; 1:242–8. [PubMed: 24917968] 
7. Capocelli KE, Fernando SD, Menard-Katcher C, Furuta GT, Masterson JC, Wartchow EP. 
Ultrastructural features of eosinophilic oesophagitis: impact of treatment on desmosomes. J Clin 
Pathol. 2015; 68:51–6. [PubMed: 25359789] 
8. Aceves SS, Newbury RO, Dohil R, Bastian JF, Broide DH. Esophageal remodeling in pediatric 
eosinophilic esophagitis. J Allergy Clin Immunol. 2007; 119:206–12. [PubMed: 17208603] 
9. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in 
active eosinophilic oesophagitis: a randomised, placebo controlled, double blind trial. Gut. 2010; 
59:21–30. [PubMed: 19828470] 
10. Aceves SS, Chen D, Newbury RO, Dohil R, Bastian JF, Broide DH. Mast cells infiltrate the 
esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF-beta1, and 
increase esophageal smooth muscle contraction. J Allergy Clin Immunol. 2010; 126:1198–204 e4. 
[PubMed: 21047675] 
11. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients 
with active eosinophilic esophagitis. Gastroenterology. 2010; 139:1526–37. 37 e1. [PubMed: 
20682320] 
Nguyen et al. Page 13
Mucosal Immunol. Author manuscript; available in PMC 2018 April 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Lucendo AJ, Arias A, De Rezende LC, et al. Subepithelial collagen deposition, profibrogenic 
cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult 
eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol. 2011; 128:1037–46. 
[PubMed: 21880354] 
13. Mishra A, Wang M, Pemmaraju VR, et al. Esophageal remodeling develops as a consequence of 
tissue specific IL-5-induced eosinophilia. Gastroenterology. 2008; 134:204–14. [PubMed: 
18166354] 
14. Beppu LY, Anilkumar AA, Newbury RO, Dohil R, Broide DH, Aceves SS. TGF-beta1-induced 
phospholamban expression alters esophageal smooth muscle cell contraction in patients with 
eosinophilic esophagitis. J Allergy Clin Immunol. 2014; 134:1100–7 e4. [PubMed: 24835503] 
15. Muir AB, Dods K, Henry SJ, et al. Eosinophilic Esophagitis-Associated Chemical and Mechanical 
Microenvironment Shapes Esophageal Fibroblast Behavior. J Pediatr Gastroenterol Nutr. 2016; 
63:200–9. [PubMed: 26727658] 
16. Muir AB, Dods K, Noah Y, et al. Esophageal epithelial cells acquire functional characteristics of 
activated myofibroblasts after undergoing an epithelial to mesenchymal transition. Exp Cell Res. 
2015; 330:102–10. [PubMed: 25183431] 
17. Muir AB, Lim DM, Benitez AJ, et al. Esophageal epithelial and mesenchymal cross-talk leads to 
features of epithelial to mesenchymal transition in vitro. Exp Cell Res. 2013; 319:850–9. 
[PubMed: 23237990] 
18. Rieder F, Nonevski I, Ma J, et al. T-helper 2 cytokines, transforming growth factor beta1, and 
eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic 
esophagitis. Gastroenterology. 2014; 146:1266–77. e1–9. [PubMed: 24486052] 
19. Cho JY, Doshi A, Rosenthal P, et al. Smad3-deficient mice have reduced esophageal fibrosis and 
angiogenesis in a model of egg induced eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 
2014; 59:10–6. [PubMed: 24590208] 
20. Kagalwalla AF, Akhtar N, Woodruff SA, et al. Eosinophilic esophagitis: epithelial mesenchymal 
transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin 
Immunol. 2012; 129:1387–96 e7. [PubMed: 22465212] 
21. Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T. Altered expression of tight junction molecules in 
alveolar septa in lung injury and fibrosis. American journal of physiology Lung cellular and 
molecular physiology. 2012; 302:L193–205. [PubMed: 22003091] 
22. Stammler A, Muller D, Tabuchi Y, Konrad L, Middendorff R. TGFbetas modulate permeability of 
the blood-epididymis barrier in an in vitro model. PLoS One. 2013; 8:e80611. [PubMed: 
24236189] 
23. Pierucci-Alves F, Yi S, Schultz BD. Transforming growth factor beta 1 induces tight junction 
disruptions and loss of transepithelial resistance across porcine vas deferens epithelial cells. 
Biology of reproduction. 2012; 86:36. [PubMed: 21957188] 
24. Harada H, Nakagawa H, Oyama K, et al. Telomerase induces immortalization of human 
esophageal keratinocytes without p16INK4a inactivation. Mol Cancer Res. 2003; 1:729–38. 
[PubMed: 12939398] 
25. Saeedi BJ, Kao DJ, Kitzenberg DA, et al. HIF dependent regulation of claudin-1 is central to 
intestinal epithelial tight junction integrity. Molecular biology of the cell. 2015; 26:2252–62. 
[PubMed: 25904334] 
26. Kc K, Rothenberg ME, Sherrill JD. In vitro model for studying esophageal epithelial 
differentiation and allergic inflammatory responses identifies keratin involvement in eosinophilic 
esophagitis. PLoS One. 2015; 10:e0127755. [PubMed: 26039063] 
27. Chen X, Oshima T, Tomita T, et al. Acidic bile salts modulate the squamous epithelial barrier 
function by modulating tight junction proteins. Am J Physiol Gastrointest Liver Physiol. 2011; 
301:G203–9. [PubMed: 21617116] 
28. Oshima T, Koseki J, Chen X, Matsumoto T, Miwa H. Acid modulates the squamous epithelial 
barrier function by modulating the localization of claudins in the superficial layers. Lab Invest. 
2012; 92:22–31. [PubMed: 21912379] 
29. Bjorkman EV, Edebo A, Oltean M, Casselbrant A. Esophageal barrier function and tight junction 
expression in healthy subjects and patients with gastroesophageal reflux disease: functionality of 
Nguyen et al. Page 14
Mucosal Immunol. Author manuscript; available in PMC 2018 April 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
esophageal mucosa exposed to bile salt and trypsin in vitro. Scand J Gastroenterol. 2013; 48:1118–
26. [PubMed: 24047393] 
30. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 
2009; 119:1417–9. [PubMed: 19487817] 
31. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nature reviews Drug 
discovery. 2012; 11:790–811. [PubMed: 23000686] 
32. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal 
integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not 
eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014; 12:1815–23 e2. [PubMed: 24657840] 
33. Ravelli A, Villanacci V, Cadei M, Fuoti M, Gennati G, Salemme M. Dilated intercellular spaces in 
eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2014; 59:589–93. [PubMed: 25023586] 
34. Simon D, Radonjic Hosli S, Straumann A, Yousefi S, Simon HU. Active eosinophilic esophagitis is 
characterized by epithelial barrier defects and eosinophil extracellular trap formation. Allergy. 
2015; 70:443–52. [PubMed: 25620273] 
35. Abe A, Takano K, Kojima T, et al. Interferon-gamma increased epithelial barrier function via 
upregulating claudin-7 expression in human submandibular gland duct epithelium. Journal of 
molecular histology. 2016; 47:353–63. [PubMed: 26956365] 
36. Farkas AE, Hilgarth RS, Capaldo CT, et al. HNF4alpha regulates claudin-7 protein expression 
during intestinal epithelial differentiation. Am J Pathol. 2015; 185:2206–18. [PubMed: 26216285] 
37. Gunzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiological 
reviews. 2013; 93:525–69. [PubMed: 23589827] 
38. Vincent T, Neve EP, Johnson JR, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex 
promotes TGF-beta mediated epithelial mesenchymal transition. Nature cell biology. 2009; 
11:943–50. [PubMed: 19597490] 
39. Lu Y, Yu L, Yang M, et al. The effects of shRNA-mediated gene silencing of transcription factor 
SNAI1 on the biological phenotypes of breast cancer cell line MCF-7. Molecular and cellular 
biochemistry. 2014; 388:113–21. [PubMed: 24293287] 
40. Mittal MK, Myers JN, Bailey CK, Misra S, Chaudhuri G. Mode of action of the retrogene product 
SNAI1P, a SNAIL homolog, in human breast cancer cells. Molecular biology reports. 2010; 
37:1221–7. [PubMed: 19277896] 
41. Pereira F, Barbachano A, Silva J, et al. KDM6B/JMJD3 histone demethylase is induced by vitamin 
D and modulates its effects in colon cancer cells. Hum Mol Genet. 2011; 20:4655–65. [PubMed: 
21890490] 
42. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 
119:1420–8. [PubMed: 19487818] 
Nguyen et al. Page 15
Mucosal Immunol. Author manuscript; available in PMC 2018 April 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. TGF-β1 diminishes esophageal epithelial barrier
Using immortalized human esophageal epithelial (EPC2-TERT) cells in a stratified 
squamous 3-dimensional air liquid interface (3D-ALI) culture, transforming growth factor-
β1 (TGF-β1) (10 ng/ml) diminished barrier as measured by (A) transepithelial electrical 
resistance (TEER) and increased permeability as measured by (B) 3kDa FITC dextran 
paracellular flux (FITC flux) (N=4–8, *p≤0.05, **p≤0.01). (C) H&E stained sections from 
EPC2-TERT cells grown in 3D-ALI culture and treated with TGF-β1 (10 ng/ml). Arrows 
indicate prominent cellular separation. Black scale bar represents 50 μm. (D) To confirm that 
TGF-β1 signaling is increased, we performed western blot densitometry which shows 
increase in protein expression of phosphorylated SMAD2/3 (pSMAD2/3) when cells are 
exposed to TGF-β1 (10 ng/ml), indicating that TGF-β1 activates SMAD2/3 via 
phosphorylation in the in vitro 3-D ALI model (N=4, *p≤0.05). (E) Representative western 
blot showing increase in protein expression of pSMAD2/3 in vitro when exposed to TGF-β1 
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(10 ng/ml). (F) Protein expression of pSMAD2/3 and total SMAD2/3 when EPC2-TERT 
cells exposed to TGF-β1 (10 ng/ml). Data are expressed as mean fold change versus 
unstimulated controls ± SEM. Treatment with recombinant human TGF-β1 (10 ng/ml) 
occurred at the start of 3D-ALI exposure and during the process of differentiation and 
stratification on days 7 and 9.
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Figure 2. TGF-β1 attenuates expression of Claudin-7
(A) Claudin mRNA expression in immortalized human esophageal epithelial (EPC2-hTERT) 
cells as mean fold change relative to CLDN1. CLDN 1, 4 and 7 were the predominantly 
expressed claudin mRNAs in the esophageal epithelium differentiated and stratified in 3D-
ALI culture. (B) Transforming growth factor-β1 (TGF-β1) exposure (10 ng/ml) led to no 
significant effect on expression of selected epithelial barrier molecules, but decreased 
expression of CLDN7 mRNA and (C) claudin-7 protein in EPC2-hTERT cells at 3D-ALI 
(N=3, *p≤0.05, **p≤0.01). (C) Representative western blot demonstrates decreased 
claudin-7 protein in the presence of TGF-β1 (10 ng/ml). (E) EPC2-hTERT cells exposed to 
TGF-β1 (10 ng/ml) leads to attenuation in claudin-7, however when exposed to TGF-β type 
1 receptor inhibitor (TGF-β RI) (5μm) prior to TGF-β1, cells were protected from the 
attenuation in claudin-7, indicating that the TGF-β1 pathway directly influences the 
attenuation of claudin-7 (N=4, ****p≤0.0001).
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Figure 3. Claudin-7 knockdown validation
Claudin-7 knockdown cells were generated with shRNA constructs targeted against CLDN7 
mRNA to determine the role of claudin-7 in epithelial barrier dysfunction independent of 
transforming growth factor-β1 (TGF-β1). (A) Western blot to assess specificity for CLDN7 
was confirmed by assessing the expression esophageal claudins (claudin-1, claudin-4 and 
claudin-7) at the protein level by western blot on scrambled shRNA control and claudin-7 
knockdown cells. (B) No significant effects on claudin-1 and claudin-4 were observed. 
Claudin-7 knockdown cells resulted in (C) 90% reduction in claudin-7 protein expression 
and (D) a 97% reduction in CLDN7 mRNA expression.
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Figure 4. Claudin-7 knockdown results in diminished esophageal epithelial barrier function
Knockdown of CLDN7 diminished barrier function as measured by (A) transepithelial 
electrical resistance (TEER) and increased permeability as measured by (B) 3kDa FITC 
dextran paracellular flux (FITC flux) (N=11, *p≤0.05, **p≤0.01). (C) H&E stained sections 
from CLDN7 knockdown cells grown in 3-dimensional air liquid interface (3D-ALI) 
culture. Arrows indicate prominent cellular separation. Black scale bar represents 50 μm. 
These data suggest that in the setting of attenuated claudin-7, epithelial barrier defects exist. 
(D) CLDN7 overexpressing cells (pLKO.1-Puro claudin-7 ORF) were generated and 
functional assessments were done in the presence and absence of TGF-β1 (10 ng/ml) in the 
3-D ALI model. There was no significant decrease in TEER and (E) no significant increase 
in paracellular flux following TGF-β1 exposure. (N=5, n.s.). (F) H&E stained sections from 
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CLDN7 overexpressing cells grown in 3D-ALI culture in the absence (top panel) and 
presence of TGF-β1 (bottom panel). Black scale bar represents 50 μm.
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Figure 5. Claudin-7 expression is decreased in pediatric subjects with EoE
CLDN7 mRNA is decreased in active eosinophilic esophagitis (EoE) (N=7) compared to 
control subjects (N=10). Levels returned to near normal following successful clinical 
treatment (inactive EoE, N=6) (**p≤0.01, ***p≤0.001).
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Figure 6. Claudin-7 immunofluorescence in pediatric subjects
Immunofluorescent staining of claudin-7 in human esophageal biopsies from pediatric (A) 
control (B) active eosinophilic esophagitis (EoE) and (C) inactive EoE subjects. 
Immunofluorescence of (B) active EoE shows a diffuse granular perimembraneous pattern 
outlining the cell membrane with staining present within in the cytoplasm of the cells in the 
suprabasal layer when compared to (A) control and (C) inactive EoE subjects which show a 
continuous linear pattern outlining the cell membrane in the suprabasal layer of the 
epithelium with a honeycomb appearance. Images at 400× magnification. White scale bar 
represents 20 μm. White scale bar in inset image represents 2 μm.
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Figure 7. pSMAD2/3 in pediatric subjects
Immunofluorescent staining of phosphorylated SMAD2/3 (pSMAD2/3) in human 
esophageal biopsies from (A) control (B) active eosinophilic esophagitis (EoE) and (C) 
inactive EoE subjects. A C at 200× magnification, white scale bar represents 50 μm. White 
dotted line represents basal lamina. (D) Quantification shows increased positive cells per 
high power field of pSMAD2/3 staining in active EoE compared to control and inactive EoE. 
(E) Western blot densitometry shows increase in protein expression of pSMAD2/3 in active 
EoE vs control and inactive EoE. (F) Western blot showing increase in protein expression of 
pSMAD2/3 in active EoE vs control and inactive EoE. (G) Relative protein expression of 
pSMAD2/3 and total SMAD2/3 in active EoE vs control and inactive EoE.
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Table 1
Expression of Tight Junction, Adherens Junction, Desmosome, and Mesenchymal genes in 
transforming growth factor-β1 (TGF-β1) exposed immortalized human esophageal 
epithelial (EPC2-hTERT cells)
Data are expressed as mean fold change versus unstimulated controls ± SEM.
Name Fold Change ± SEM TGF-β1 (10 ng/ml) Significance
Tight Junction
Claudin-1 1.27 ± 0.13 n.s.
Claudin-4 0.63 ± 0.12 n.s.
Claudin-7 0.45 ± 0.02 p<0.01
Occludin 0.91 ± 0.14 n.s.
Zonula Occluden-1 0.79 ± 0.16 n.s.
Adherens Junction
E-Cadherin 1.04 ± 0.01 n.s.
Desmosome
Desmoglein-1 1.09 ± 0.30 n.s.
Desmoglein-2 1.42 ± 0.17 n.s.
Desmoglein-3 1.14 ± 0.33 n.s.
Mesenchymal
Connective Tissue Growth Factor 0.88 ± 0.33 n.s.
Smooth Muscle α Actin 1.16 ± 0.23 n.s.
N-Cadherin 49.69 ± 11.12 p<0.05
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